TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days

The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain. The purpose of this work was to test if thrombus aspiration reduces mortality.

This was a multicenter, prospective, randomized and controlled study that included patients with ST-segment elevation myocardial infarction within 24 hours of evolution. The catheters used were Eliminate (Terumo), Export (Medtronic) and Pronto (Vascular Solutions). The primary endpoint was mortality at 30 days and the secondary endpoints rehospitalization due to heart attack and stent thrombosis at 30 days.

The study included 7244 patients randomized to manual thrombus aspiration and angioplasty (3621 patients) or angioplasty (3623 patients). Mortality from all causes occurred in 2.8% of the thrombus aspiration group vs 3% of the group without thrombus aspiration (HR, 0.94; 95% CI, 0.72 – 1.22; p = 0.63). The rate of rehospitalization for heart attack at 30 days was 0.5% vs 0.9% (HR, 0.61; 95% CI, 0.34 – 1.07; p= 0.09) and for stent thrombosis 0.2% vs 0.5% respectively (HR, 0.47; 95% CI, 0.20 – 1.02; p= 0.06). There was no difference between the two groups for stroke.

The results were consistent in all the prespecified groups, including the subgroups according to thrombus burden and initial coronary flow.

Conclusion:

Routine thrombus aspiration before primary angioplasty does not reduce mortality, rehospitalization or stent thrombosis at 30 days compared to angioplasty alone in patients with ST-segment elevation myocardial infarction.

Editorial comment:

According to the guidelines (ACC/AHA/ESC) thrombus aspiration in myocardial infarction is class IIA. A recent publication in Eurointervention showed that only 36% of interventionist cardiologists routinely perform thrombus aspiration. In terms of the negative results, an editorial published in NEJM by Drs. Robert Byrne and Adnan Kastrati emphasizes that the benefit over cardiac remodeling and myocardial recovery may not be evident at 30 days.

Read editorial

Read article 

Ole%20Frobert_slides
Ole Frobert
2013-09-02

Original title: TASTE: Thrombus aspiration during ST-segment elevation myocardial infarction. A multicenter, prospective, registry based randomized clinical trial.

More articles by this author

INTIME: Home monitoring of severe heart failure patients gives promising results.

Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight or arrhythmias. The home monitoring device has...

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of...

260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified...

PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.

The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a...

LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.

Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5% and 7% of these patients survive and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....